

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/010163 A1

(51) International Patent Classification⁷: C07D 407/04,
409/04, A61K 31/381, 31/47, 31/404

SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/SE02/01402

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 19 July 2002 (19.07.2002)

(25) Filing Language: English

Declarations under Rule 4.17:

(30) Priority Data:
0102617-8 25 July 2001 (25.07.2001) SE

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG)

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

— of inventorship (Rule 4.17(iv)) for US only

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRIFFITHS, David [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). JOHNSTONE, Craig [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(I)

(57) Abstract: The invention relates to thiophene carboxamides of formula (I), wherein R₁, R₂, R₃, A, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

THIS PAGE BLANK (USPTO)

NOVEL COMPOUNDS

Field of the Invention

5 The present invention relates to thiophene carboxamide derivatives, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Background of the Invention

10 The NF- κ B (nuclear factor κ B) family is composed of homo- and heterodimers of the Rel family of transcription factors. A key role of these transcription factors is to induce and coordinate the expression of a broad spectrum of pro-inflammatory genes including cytokines, chemokines, interferons, MHC proteins, growth factors and cell adhesion molecules (for reviews see Verma et. al., Genes Dev. 9:2723-35, 1995; Siebenlist et. al., Ann. Rev. Cell. Biol. 10:405-455, 1994; Bauerle and Henkel, Ann. Rev. Immunol., 12:141-179, 1994; Barnes and Karin, New Engl. J. Med., 336:1066-1071, 1997).

20 The most commonly found Rel family dimer complex is composed of p50 NFkB and p65 RelA (Baeuerle and Baltimore, Cell 53:211-217, 1988; Baeuerle and Baltimore, Genes Dev. 3:1689-1698, 1989). Under resting conditions NF- κ B dimers are retained in the cytoplasm by a member of the I κ B family of inhibitory proteins (Beg et. al., Genes Dev., 7:2064-2070, 1993; Gilmore and Morin, Trends Genet. 9:427-433, 1993; Haskil et. al., Cell 65:1281-1289, 1991). However, upon cell activation by a variety of cytokines or other 25 external stimuli, I κ B proteins become phosphorylated on two critical serine residues (Traenckner et. al., EMBO J., 14:2876, 1995) and are then targeted for ubiquitination and proteosome-mediated degradation (Chen, Z.J. et. al., Genes and Dev. 9:1586-1597, 1995; Scherer, D.C. et. al., Proc. Natl. Acad. Sci. USA 92:11259-11263, 1996; Alkalay, I. et. al., Proc. Natl. Acad. Sci. USA 92:10599-10603, 1995). The released NF- κ B is then able to 30 translocate to the nucleus and activate gene transcription (Beg et.al., Genes Dev., 6:1899-1913, 1992).

A wide range of external stimuli have been shown to be capable of activating NF- κ B (Baeuerle, P.A., and Baichwal, V.R., Adv. Immunol., 65:111-136, 1997). Although the majority of NF- κ B activators result in I κ B phosphorylation, it is clear that multiple pathways lead to this key event. Receptor-mediated NF- κ B activation relies upon specific interactions between the receptor and adapter/signalling molecules (for example, TRADD, RIP, TRAF, MyD88) and associated kinases (IRAK, NIK) (Song et. al., Proc. Natl. Acad. Sci. USA 94:9792-9796, 1997; Natoli et. al., JBC 272:26079-26082, 1997). Environmental stresses such as UV light and γ -radiation appear to stimulate NF- κ B via alternative, less defined, mechanisms.

Recent publications have partially elucidated the NF- κ B activation. This work has identified three key enzymes which regulate specific I κ B/NF- κ B interactions: NF- κ B inducing kinase (NIK) (Boldin et. al., Cell 85:803-815, 1996), I κ B kinase-1 (IKK-1) (Didonato et. al., Nature 388:548, 1997; Regnier et. al., Cell 90:373 1997) and I κ B kinase-2 (IKK-2) (Woronicz et. al., Science 278:866, 1997; Zandi et. al., Cell 91:243, 1997).

NIK appears to represent a common mediator of NF- κ B signalling cascades triggered by tumour necrosis factor and interleukin-1, and is a potent inducer of I κ B phosphorylation. However NIK is unable to phosphorylate I κ B directly.

IKK-1 and IKK-2 are thought to lie immediately downstream of NIK and are capable of directly phosphorylating all three I κ B sub-types. IKK-1 and IKK-2 are 52% identical at the amino acid level but appear to have similar substrate specificities; however, enzyme activities appear to be different: IKK-2 is several-fold more potent than IKK-1. Expression data, coupled with mutagenesis studies, suggest that IKK-1 and IKK-2 are capable of forming homo- and heterodimers through their C-terminal leucine zipper motifs, with the heterodimeric form being preferred (Mercurio et. al., Mol. Cell Biol., 19:1526, 1999; Zandi et. al., Science; 281:1360, 1998; Lee et. al, Proc. Natl. Acad. Sci. USA 95:9319, 1998).

NIK, IKK-1 and IKK-2 are all serine/threonine kinases. Recent data has shown that tyrosine kinases also play a role in regulating the activation of NF- κ B. A number of groups

have shown that TNF- α induced NF- κ B activation can be regulated by protein tyrosine phosphatases (PTPs) and tyrosine kinases (Amer et. al., JBC 273:29417-29423, 1998; Hu et. al., JBC 273:33561-33565, 1998; Kaekawa et. al., Biochem. J. 337:179-184, 1999; Singh et. al., JBC 271 31049-31054, 1996). The mechanism of action of these enzymes appears to be in regulating the phosphorylation status of I κ B. For example, PTP1B and an unidentified tyrosine kinase appear to directly control the phosphorylation of a lysine residue (K42) on I κ B- α , which in turn has a critical influence on the accessibility of the adjacent serine residues as targets for phosphorylation by IKK.

Several groups have shown that IKK-1 and IKK-2 form part of a 'signalosome' structure in association with additional proteins including IKAP (Cohen et. al., Nature 395:292-296, 1998; Rothwarf et. al., Nature 395:297-300, 1998), MEKK-1, putative MAP kinase phosphatase (Lee et. al., Proc. Natl. Acad. Sci. USA 95:9319-9324, 1998), as well as NIK and I κ B. Data is now emerging to suggest that although both IKK-1 and IKK-2 associate with NIK, they are differentially activated, and therefore might represent an important integration point for the spectrum of signals that activate NF- κ B. Importantly, MEKK-1 (one of the components of the putative signalosome and a target for UV light, LPS induced signalling molecules and small GTPases) has been found to activate IKK-2 but not IKK-1. Similarly, NIK phosphorylation of IKK-1 results in a dramatic increase in IKK-1 activity but only a small effect on IKK-2 (for review, see Mercurio, F., and Manning, A.M., Current Opinion in Cell Biology, 11:226-232, 1999).

Inhibition of NF- κ B activation is likely to be of broad utility in the treatment of inflammatory disease.

25

There is accumulating evidence that NF- κ B signalling plays a significant role in the development of cancer and metastasis. Abnormal expression of c-Rel, NF- κ B2 or I κ B α have been described in a number of tumour types and tumour cell lines, and there is now data to show that constitutive NF- κ B signalling via IKK2 takes place in a wide range of tumour cell lines. This activity has been linked to various upstream defects in growth factor signalling such as the establishment of autocrine loops, or the presence of oncogene

products e.g. Ras, AKT, Her2, which are involved in the activation of the IKK complex. Constitutive NF- κ B activity is believed to contribute to oncogenesis through activation of a range of anti-apoptotic genes e.g. A1/Bfl-1, IEX-1, XIAP, leading to the suppression of cell death pathways, and transcriptional upregulation of cyclin D1 which promotes cell growth. Other data indicate that this pathway is also likely to be involved in the regulation of cell adhesion and cell surface proteases. This suggests a possible additional role for NF- κ B activity in the development of metastasis. Evidence confirming the involvement of NF- κ B activity in oncogenesis includes the inhibition of tumour cell growth in vitro and in vivo on expression of a modified form of I κ B α (super-repressor I κ B α).

10


In addition to the constitutive NF- κ B signalling observed in many tumour types, it has been reported that NF- κ B is also activated in response to certain types of chemotherapy. Inhibition of NF- κ B activation through expression of the super-repressor form of I κ B α in parallel with chemotherapy treatment has been shown to enhance the antitumour effect of the chemotherapy in xenograft models. NF- κ B activity is therefore also implicated in inducible chemoresistance.

15

Disclosure of the Invention

20

According to the present invention, there is provided a compound of formula (I)



in which:

R¹ represents NH₂ or R¹ represents a methyl group optionally substituted by one or more groups selected independently from C₁-C₄ alkyl, C₃-C₆ cycloalkyl, halogen, hydroxyl, 5 C₁-C₄ alkoxy, S(O)_vCH₃ and NR⁴R⁵;

X represents O or S;

R² represents hydrogen, halogen, cyano, nitro, -NR⁶R⁷, -CONR⁶R⁷, -COOR⁶, 10 -NR⁶COR⁷, -S(O)_mR⁶, -SO₂NR⁶R⁷, -NR⁶SO₂R⁷, C₁-C₂ alkyl, trifluoromethyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, trifluoromethoxy, C₁-C₂ alkoxy or C₁-C₂ alkanoyl;

A represents a fused bicyclic ring system wherein one ring is a phenyl ring or a 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently 15 from O, N and S; and the other ring is either a fused phenyl ring or a fused 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S; or a fused 5- to 7-membered saturated ring optionally incorporating one to three heteroatoms selected independently from oxygen, nitrogen and sulphur; said fused bicyclic ring system being optionally substituted by one or more substituents selected 20 independently from halogen, cyano, nitro, -NR⁸COR⁹, -S(O)_sR⁸, -SO₂NR⁸R⁹, -NR⁸SO₂R⁹ and C₁-C₆ alkyl;

n represents an integer 0, 1 or 2; and when n represents 2, each R³ group may be selected 25 independently;

R³ represents a group -W-Y-Z wherein:

W represents O, S(O)_r, NR¹³, CH₂, -CH₂-O- or a bond;

Y represents a bond or Y represents a group $-(CH_2)_p-X-(CH_2)_q-$ wherein p and q independently represent an integer 0, 1 or 2; and X represents O, $-CO-$ or $CR^{14}R^{15}$;

5 R¹⁴ and R¹⁵ independently represent H, CH₃ or F;

or R¹⁴ represents H or CH₃ and R¹⁵ represents hydroxyl or OCH₃;

or the group CR¹⁴R¹⁵ together represents a C₃-C₆ cycloalkyl ring;

10

Z represents:

(a) a phenyl ring or a 5- or 6-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S; said phenyl or heteroaromatic ring being optionally substituted by one or more substituents selected independently from halogen, cyano, -NR¹⁶R¹⁷, -CONR¹⁶R¹⁷, -COOR¹⁶, -COR¹⁶-NR¹⁶COR¹⁷, -S(O)_uR¹⁶, -SO₂NR¹⁶R¹⁷, -NR¹⁶SO₂R¹⁷, hydroxyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkyl and C₁-C₆ alkoxy; said alkyl or alkoxy group being optionally further substituted by one or more groups selected from halogen, cyano, hydroxyl, C₁-C₄ alkoxy and NR¹⁸R¹⁹; or

20

(b) a saturated 3- to 7-membered ring optionally incorporating one or two heteroatoms selected independently from O, N and S, and optionally incorporating a carbonyl group; said saturated ring being optionally substituted by one or more substituents selected independently from halogen, cyano, -NR¹⁶R¹⁷, -CONR¹⁶R¹⁷, -COOR¹⁶, -COR¹⁶, -NR¹⁶COR¹⁷, -S(O)_uR¹⁶, -SO₂NR¹⁶R¹⁷, -NR¹⁶SO₂R¹⁷, hydroxyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkyl and C₁-C₆ alkoxy; said alkyl or alkoxy group being optionally further substituted by one or more groups selected from halogen, cyano, hydroxyl, C₁-C₄ alkoxy and NR¹⁸R¹⁹; or

(c) Z represents hydroxyl, C₁-C₆ alkoxy, CF₃, CHF₂, CH₂F or NR²⁰R²¹ where R²⁰ and R²¹ are independently hydrogen or C₁-C₄ alkyl optionally substituted by C₁-C₄ alkoxy;

5 R⁴ and R⁵ independently represent H or C₁-C₄ alkyl; or the group NR⁴R⁵ represents a 5- or 6-membered saturated azacyclic ring optionally containing a further O, S or NR²³ group; where R²³ is hydrogen or C₁-C₄ alkyl;

10 R⁶ and R⁷ independently represent H or C₁-C₂ alkyl;

R⁸ and R⁹ independently represent H or C₁-C₆ alkyl;

R¹³ represents H or C₁-C₄ alkyl;

15 R¹⁶ and R¹⁷ independently represent H or C₁-C₆ alkyl; or the group NR¹⁶R¹⁷ represents a 5- or 6-membered saturated azacyclic ring optionally containing a further O, S or NR²⁴ group; where R²⁴ is hydrogen or C₁-C₆ alkyl;

20 R¹⁸ and R¹⁹ independently represent H or C₁-C₄ alkyl; or the group NR¹⁸R¹⁹ represents a 5- or 6-membered saturated azacyclic ring optionally containing a further O, S or NR²⁵ group; where R²⁵ is hydrogen or C₁-C₄ alkyl;

m, r, s, u and v independently represent an integer 0, 1 or 2;

25 and pharmaceutically acceptable salts thereof.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

5

In one embodiment, X represents oxygen.

In another embodiment, R¹ represents CH₃ or NH₂. In a more particular embodiment, R¹ represents NH₂.

10

The compounds of formula (I) and their pharmaceutically acceptable salts have the advantage that they are inhibitors of the enzyme IKK2.

15

The invention further provides a process for the preparation of compounds of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

According to the invention there is also provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament.

20

Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of IKK2 activity is beneficial.

25

Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.

30

According to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which inhibition of IKK2 activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition,

a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

There is also provided a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In particular embodiments, the fused bicyclic ring system A represents optionally substituted quinoline, indole, benzothiophene, benzofuran, tetrahydroisoquinoline, 1,3-benzodioxolane (methylenedioxyphenyl) and 1,4-benzodioxane (ethylenedioxyphenyl).

In one embodiment, the group R² in formula (I) represents H, halogen or C₁-C₂ alkyl. In another embodiment, the group R² represents H or methyl. In yet another embodiment, the group R² in formula (I) represents H.

Particular compounds of the invention include those exemplified herein:
2-[(aminocarbonyl)amino]-5-(2-benzofuranyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(3-quinolinyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(8-quinolinyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-benzothiophenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(3-benzothiophenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(5-indolyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-4-methyl-5-(1,4-benzodioxan-6-yl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-4-methyl-5-(3-indolyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-4-methyl-5-(1,3-benzodioxo-5-yl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(1*H*-indol-2-yl)thiophene-3-carboxamide;
3-[(aminocarbonyl)amino]-5-(1-benzothien-3-yl)thiophene-2-carboxamide;
2-[(aminocarbonyl)amino]-5-(2-morpholin-4-ylmethylbenzo[b]thiophen-5-yl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-[4-(2-morpholin-4-ylethoxy)-1-benzothien-2-yl]-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-{2-[4-methylphenylsulphonyl]-1,2,3,4-tetrahydroisoquinolin-6-yl}thiophene-3-carboxamide;

5 3-[(aminocarbonyl)amino]-5-(1-benzothien-2-yl)thiophene-2-carboxamide;
and pharmaceutically acceptable salts thereof.

Unless otherwise indicated, the term "C₁-C₆ alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 6 carbon atoms. Examples of such groups 10 include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl. The terms "C₁-C₂ alkyl" and "C₁-C₄ alkyl" are to be interpreted analogously.

Unless otherwise indicated, the term "C₂-C₃ alkenyl" referred to herein denotes a straight or branched chain alkyl group having 2 or 3 carbon atoms incorporating at least one 15 carbon-carbon double bond. Examples of such groups include ethenyl and propenyl. The term "C₂-C₆ alkenyl" is to be interpreted analogously.

Unless otherwise indicated, the term "C₂-C₃ alkynyl" referred to herein denotes a straight chain alkyl group having 2 or 3 carbon atoms incorporating one carbon-carbon triple bond. 20 Examples of such groups include ethynyl and propynyl. The term "C₂-C₆ alkynyl" is to be interpreted analogously.

Unless otherwise indicated, the term "C₃-C₆ cycloalkyl" referred to herein denotes a saturated carbocyclic ring having from 3 to 6 carbon atoms. Examples of such groups 25 include cyclopropyl, cyclopentyl and cyclohexyl.

Unless otherwise indicated, the term "C₁-C₄ alkoxy" referred to herein denotes a straight or branched chain alkoxy group having 1 to 4 carbon atoms. Examples of such groups

include methoxy, ethoxy and isopropoxy. The terms "C₁-C₂ alkoxy" and "C₁-C₆ alkoxy" are to be interpreted analogously.

Unless otherwise indicated, the term "C₁-C₂ alkanoyl" referred to herein denotes a formyl or acetyl group.

Unless otherwise indicated, the term "halogen" referred to herein denotes fluoro, chloro, bromo and iodo.

Examples of a 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S include furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, pyridine, pyridazine, pyrimidine and pyrazine. The term "a 5- or 6-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S" is to be interpreted analogously.

Examples of a saturated 5- to 7-membered ring optionally incorporating one to three heteroatoms selected independently from O, N and S include cyclopentyl, cyclohexyl, tetrahydrofuran, pyrrolidine, piperidine, piperazine and morpholine.

Examples of a fused bicyclic ring system wherein one ring is a phenyl ring or a 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S; and the other ring is either a fused phenyl ring or a fused 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S; or a fused 5- to 7-membered saturated ring optionally incorporating one to three heteroatoms selected independently from oxygen, nitrogen and sulphur include naphthyl, quinoline, isoquinoline, tetrahydroisoquinoline, indole, benzothiophene, benzofuran, benzimidazole, 1,3-benzodioxolane (methylenedioxyphenyl) and 1,4-benzodioxane (ethylenedioxyphenyl).


Examples of a 5- or 6-membered saturated azacyclic ring optionally containing a further O, S or NR group include pyrrolidine, piperidine, piperazine and morpholine.

Examples of a saturated 3- to 7-membered ring optionally incorporating one or two heteroatoms selected independently from O, N and S, and optionally incorporating a carbonyl group include cyclopropyl, cyclohexyl, pyrrolidine, piperidine, morpholine, tetrahydrofuran, piperidin-2-one and piperidine-4-one.

According to the invention there is also provided a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof which comprises:


10

(a) reaction of a compound of formula (II):




wherein A, R², R³ and n are as defined in formula (I) with an isocyanate or an
15 isothiocyanate or an acyl derivative, R¹-CO-L where L is a leaving group; or

(b) reaction of compound of formula (III)




wherein R^3 , n and A are as defined in formula (I)
with a compound of formula (IV)



5


wherein X, R^1 and R^2 are as defined in formula (I) and LG represents a leaving group; or

(c) reaction of compound of formula (V)



10

wherein R^3 , n and A are as defined in formula (I) and LG represents a leaving group,
with a compound of formula (VI)



15

wherein X, R¹ and R² are as defined in formula (I);

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

In process (a), suitable isocyanate reagents include trimethylsilylisocyanate, trimethylsilylisothiocyanate, chlorosulphonylisocyanate, trichloroacetylisocyanate and sodium isocyanate. The reaction with trimethylsilylisocyanate or trimethylsilylisothiocyanate can be carried out in a solvent such as dichloromethane/dimethylformamide at a suitable elevated temperature, for example, at the reflux temperature of the reaction mixture. The reaction with chlorosulphonylisocyanate can be carried out in a solvent such as toluene at ambient temperature. The reaction with sodium isocyanate can be carried out in a suitable solvent system such as aqueous acetic acid at ambient temperature. The trichloroacetylisocyanate reaction can be carried out in a suitable solvent system such as acetonitrile at ambient temperature, and subsequently treating the mixture with ammonia to give compounds of the general formula (I).

Suitable acyl derivatives of formula R¹-CO-L include acyl halides, particularly acyl chlorides, and acid anhydrides. Reactions with such acyl derivatives are generally carried out at ambient temperature in a suitable solvent such as pyridine, or in a solvent such as dichloromethane in the presence of a suitable base such as triethylamine or pyridine. Compounds of formula (I) wherein X represents O may subsequently be converted into corresponding compounds of formula (I) wherein X represents S by reaction with, for example, Lawesson's reagent.

In processes (b) and (c), the compounds of formulae (III) and (IV) or of formulae (V) and (VI) are reacted together under catalysis provided by a complex of a transition metal such as palladium or nickel. In compounds of formulae (III) and (VI), under appropriate conditions, "metal" can be a metal or semi-metal such as magnesium, zinc, copper, tin,

silicon, zirconium, aluminium or boron. Suitable leaving groups include iodo, bromo, chloro, triflate or phosphonate.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the addition and removal of one or more protecting groups.


10 The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 3rd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1999).

15 The present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from

20 hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.

25 Salts of compounds of formula (I) may be formed by reacting the free base, or a salt, enantiomer or racemate thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed *in vacuo* or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.


Compounds of formula (II) can be prepared by standard chemistry described in the literature [for example, J. Het. Chem. 36, 333 (1999)] or by reaction of compounds of formula (VII):



where A, R², R³ and n are as defined in formula (I), and L represents a leaving group, with ammonia. Suitable groups L include halogen, in particular chloro.

Compounds of formula (VII) where L is halo can be prepared from the corresponding compound of formula (VIII):

10



where A, R², R³ and n are as defined in formula (I), by treating with a halogenating agent such as thionyl chloride.

15

Compounds of formulae (III), (IV), (V), (VI) and (VIII) are commercially available or can be prepared using standard chemistry as exemplified herein.

Certain novel intermediate compounds form a further aspect of the invention.

The compounds of formula (I) have activity as pharmaceuticals, in particular as IKK2 enzyme inhibitors, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals in which inhibition of IKK2 is beneficial. Examples of such conditions/diseases include inflammatory diseases or diseases with an inflammatory component. Particular diseases include inflammatory arthritides including rheumatoid arthritis, osteoarthritis, spondylitis, Reiters syndrome, psoriatic arthritis, lupus and bone resorptive disease; multiple sclerosis, inflammatory bowel disease including Crohn's disease; asthma, chronic obstructive pulmonary disease, emphysema, rhinitis, myasthenia gravis, Graves' disease, allograft rejection, psoriasis, dermatitis, allergic disorders, immune complex diseases, cachexia, ARDS, toxic shock, heart failure, myocardial infarcts, atherosclerosis, reperfusion injury, AIDS, cancer and disorders characterised by insulin resistance such as diabetes, hyperglycemia, hyperinsulinemia, dyslipidemia, obesity, polycystic ovarian disease, hypertension, cardiovascular disease and Syndrome X.

The reported roles of NF- κ B in both oncogenesis and chemoresistance suggest that inhibition of this pathway through the use of an IKK2 inhibitor, such as a small molecule IKK2 inhibitor, could provide a novel monotherapy for cancer and/or an important adjuvant therapy for the treatment of chemoresistant tumours.

We are particularly interested in diseases selected from asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease including Crohn's disease, multiple sclerosis, chronic obstructive pulmonary disease, bone resorptive disease, osteoarthritis, diabetes/glycaemic control and cancer.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

- 5 In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of diseases or conditions in which modulation of the IKK2 enzyme activity is beneficial.
- 10 In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

- 20 The invention still further provides a method of treating an IKK2 mediated disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined.
- 25 The invention also provides a method of treating an inflammatory disease, especially asthma, rheumatoid arthritis or multiple sclerosis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

5 The compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99
10 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

15 The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

20 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.

25 The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example,
30 "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.

The invention is illustrated, but in no way limited, by the following examples:

Example 1

5 2-[(Aminocarbonyl)amino]-5-(2-benzofuranyl)-3-thiophenecarboxamide

a) 2-Amino-3-thiophenecarboxamide

The title compound was synthesised as follows using the method described in Bull.Soc.Chim.France 2804 (1974).

10 A suspension of 2,5-dihydroxy-1,4-dithiane (25 g) and cyanoacetamide (19.3 g) in ethanol (120 ml) was stirred and heated to 50 °C. Triethylamine (9.2 ml) was added over 15 minutes and the mixture was stirred at 50 °C for a further 2 h. After cooling in ice, the solid was filtered off and dried (21.4 g).

MS (ES) 143 (M+H)⁺.

15

b) 2-[(Aminocarbonyl)amino]-3-thiophenecarboxamide

2-Amino-3-thiophenecarboxamide (0.44 g) was suspended in acetonitrile (25 ml) and trichloroacetylisocyanate (0.2 ml) added dropwise with stirring over 10 minutes. Stirring was continued for a further 3 h at room temperature and then a solution of ammonia in methanol (10 ml of a 2M solution) was added and stirring was continued for a further 2 h. The solvent was evaporated and the residue treated with water. The resultant solid was filtered off and washed with more water. Trituration with ether gave the title urea (0.2 g).
MS (ES) 186 (M+H)⁺.

25

c) 2-[(Aminocarbonyl)amino]-5-bromo-3-thiophenecarboxamide

2-[(Aminocarbonyl)amino]-3-thiophenecarboxamide (1.0 g) was dissolved in acetic acid (20 ml) and a solution of bromine (0.35 ml) in acetic acid (5 ml) was added over 5 minutes with rapid stirring. The mixture was stirred for 90 minutes and then added to water (50 ml). The product was filtered off and washed with water and dried under vacuum (0.55 g).
MS (ES) 262/264 (M-H)⁻.

¹H NMR (DMSO-D₆) 7.15 (m, 1H), 7.35 (m, 1H), 7.8 (s, 1H), 7.9 (m, 1H), 10.63 (brs, 1H).

d) 2-[(Aminocarbonyl)amino]-5-(2-benzofuranyl)-3-thiophenecarboxamide

5 A solution of 2-[(aminocarbonyl)amino]-5-bromo-3-thiophenecarboxamide (0.26 g), sodium carbonate (0.23 g) and benzofuran-2-boronic acid (0.32 g) in dimethoxyethane (60 ml) and water (2 ml) was purged with argon for 10 minutes. Tetrakis(triphenylphosphine)palladium (0.2 g) was then added and the mixture refluxed with stirring for 7 h. After cooling, the mixture was screened and evaporated. The residue 10 was partitioned between ethyl acetate and 3N sodium carbonate solution and the solid interface layer was filtered off (0.2 g).

MS (ES) 300 (M-H)⁺.

¹H NMR (DMSO-D₆) 6.9 (s, 1H), 7.05 (m, 2H), 7.2 (m, 2H), 7.3 (m, 1H); 7.6 (m, 3H), 7.8 (m, 2H), 11.15 (brs, 1H).

15

Example 2

2-[(Aminocarbonyl)amino]-5-(3-quinolinyl)-3-thiophenecarboxamide

20 Prepared by the method of Example 1 (d) but using quinoline-3-boronic acid.

MS (ES) 311 (M-H)⁺.

¹H NMR (DMSO-D₆) 7.0 (m, 2H), 7.4 (m, 1H), 7.6 (m, 2H), 7.65 (m, 2H), 8.0 (m, 2H), 8.4 (s, 1H), 9.15 (s, 1H), 11.06 (brs, 1H).

25

Example 3

2-[(Aminocarbonyl)amino]-5-(8-quinolinyl)-3-thiophenecarboxamide

Prepared by the method of Example 1 (d) but using quinoline-8-boronic acid.

30 MS (ES) 311 (M-H)⁺.

¹H NMR (DMSO-D6) 6.9 (m, 2H), 7.2 (m, 1H), 7.6 (m, 2H), 7.7 (m, 1H), 7.8 (d, 1H), 8.1 (m, 2H), 8.4 (d, 1H), 9.0 (m, 1H), 11.01 (brs, 1H).

Example 4

5

2-[(Aminocarbonyl)amino]-5-(2-benzothiophenyl)-3-thiophenecarboxamide

Prepared by the method of Example 1 (d) but using benzothiophene-2-boronic acid.

MS (ES) 316 (M-H).

10 ¹H NMR (DMSO-D6) 7.0 (m, 2H), 7.35 (m, 3H), 7.4 (s, 1H), 7.6 (s, 1H), 7.8 (d, 1H), 7.85 (m, 1H), 7.9 (d, 1H), 11.09 (s, 1H).

Example 5

15 2-[(Aminocarbonyl)amino]-5-(3-benzothiophenyl)-3-thiophenecarboxamide

Prepared by the method of Example 1 (d) but using benzothiophene-3-boronic acid.

MS (ES) 316 (M-H).

1 ¹H NMR (DMSO-D6) 6.95 (m, 2H), 7.25 (m, 1H), 7.4 (m, 2H), 7.65 (s, 1H), 7.7 (s, 1H),
20 7.8 (m, 1H), 8.0 (d, 1H), 8.2 (d, 1H), 11.08 (brs, 1H).

Example 6

2-[(Aminocarbonyl)amino]-5-(5-indolyl)-3-thiophenecarboxamide

25

Prepared by the method of Example 1 (d) but using indole-5-boronic acid.

MS (ES) 299 (M-H).

1 ¹H NMR (DMSO-D6) 6.4 (s, 1H), 6.8 (m, 2H), 7.2 (m, 1H), 7.3 (m, 3H), 7.6 (s, 1H), 7.65 (m, 1H), 7.7 (s, 1H), 10.91 (s, 1H), 11.0 (brs, 1H).

Example 72-[(Aminocarbonyl)amino]-4-methyl-5-(1,4-benzodioxan-6-yl)-3-thiophenecarboxamide5 a) 2-Amino-4-methyl-5-(1,4-benzodioxan-6-yl)-3-thiophenecarboxamide

1,4-Benzodioxan-6-yl acetone (1.7 g), cyanoacetamide (0.84 g), sulphur (0.36 g) and morpholine (1 ml) in ethanol (5 ml) were stirred and heated at 55 °C for 6 h. The reaction mixture was cooled and screened from a little insoluble before adding to water (150 ml). The precipitated solid was filtered off, washed with water and then dried. The product was then triturated with ether and collected (1.0 g).

10 MS (EI) 266 (M)⁺.

¹H NMR (DMSO-D6) 7.4 (2H, d), 7.3 (2H, d), 6.9 (2H, s), 6.8 (2H, s), 2.2 (3H, s).

15 b) 2-[(Aminocarbonyl)amino]-4-methyl-5-(1,4-benzodioxan-6-yl)-3-thiophenecarboxamide

2-Amino-4-methyl-5-(1,4-benzodioxan-6-yl)-3-thiophenecarboxamide (0.44 g) was dissolved in tetrahydrofuran (10 ml), cooled to 0 °C and trichloroacetylisocyanate (0.11 ml) added dropwise with stirring. Stirring was continued for a further 30 minutes at room temperature and then a solution of ammonia in methanol (8 ml of a 10% solution) was added and stirring was continued for a further 3 h. The solvent was evaporated and the residue treated with ethyl acetate and the product filtered off.

20 MS (ES) 332 (M-H)⁻.

¹H NMR (DMSO-D6) 2.2 (s, 3H), 4.25 (s, 4H), 6.7 (m, 2H), 6.8 (m, 2H), 6.9 (m, 1H), 7.2 (br, 1H), 10.01 (brs, 1H).

Example 82-[(Aminocarbonyl)amino]-4-methyl-5-(3-indolyl)-3-thiophenecarboxamide

Prepared by the method of Example 7 but using indol-3-acetone.

MS (ES) 313 (M-H)⁺

¹H NMR (DMSO-D6) 2.2 (s, 3H), 6.65 (brs, 2H), 7.05 (m, 1H), 7.1 (m, 1H), 7.2 (m, 2H), 7.4 (m, 1H), 7.45 (d, 1H), 7.55 (d, 1H), 10.14 (brs, 1H), 11.3 (m, 1H).

5

Example 9

2-[(Aminocarbonyl)amino]-4-methyl-5-(1,3-benzodioxolan-5-yl)-3-thiophenecarboxamide

Prepared by the method of Example 7 but using 1,3-benzodioxolan-5-acetone.

10 MS (ES) 318 (M-H)⁺

¹H NMR (DMSO-D6) 2.2 (s, 3H), 6.05 (s, 2H), 6.8 (m, 1H), 6.9 (m, 1H), 6.95 (m, 1H), 7.1 (m, 2H), 7.2 (m, 2H).

Example 10

15

2-[(Aminocarbonyl)amino]-5-(1*H*-indol-2-yl)thiophene-3-carboxamide

a) The title compound was prepared by treating 2-[(aminocarbonyl)amino]-5-(1*H*-1-*tert*-butyloxycarbonylindol-2-yl)thiophene-3-carboxamide with a mixture of 90% trifluoroacetic acid / 10% water at ambient temperature for 4h. Evaporation gave a solid (250 mg) which was washed with water.

20 MS (ES) 301 (M+H)⁺.

¹H NMR (DMSO-D6) 6.5 (s, 1H), 6.95 (m, 4H), 7.35 (m, 2H), 7.45 (d, 1H), 7.6 (s, 1H), 7.62 (brs, 1H), 10.9 (s, 1H), 11.32 (brs, 1H).

25

b) 2-[(Aminocarbonyl)amino]-5-(1*H*-1-*tert*-butyloxycarbonylindol-2-yl)thiophene-3-carboxamide

The title compound (500 mg) was prepared from 1*H*-1-(*tert*-butoxycarbonyl)indol-2-yl boronic acid in a similar manner to Example 1(d) except that the product was obtained as a

solid by filtration of the reaction mixture and was washed sequentially with 2N sodium hydroxide solution, water and methanol.

MS (ES) 401 ($M+H$)⁺.

¹H NMR (DMSO-D6) 1.4 (s, 9H), 6.7 (m, 1H), 6.95 (brs, 2H), 7.2 (m, 3H), 7.4 (m, 1H), 5 7.6 (s, 1H), 7.65 (brs, 1H), 8.0 (m, 1H), 11.04 (brs, 1H).

Example 11

3-[(Aminocarbonyl)amino]-5-(1-benzothien-3-yl)thiophene-2-carboxamide

10

a) 2-Bromothiophene-4-carboxylic acid

Prepared according to the method as described in *J. Am. Chem. Soc.*, 1954, **76**, 2445.

MS (ES) 205 ($M-H$) .

¹H NMR (DMSO-D6) 7.45 (s, 1H), 8.22 (s, 1H), 12.94 (brs, 1H).

15

b) 2-Bromo-4-(*N*-*t*-butyloxycarbonyl)aminothiophene

2-Bromothiophene-4-carboxylic acid (3 g) was dissolved in dry warm *t*-butanol (24 ml). Triethylamine (2.02 ml) was added followed by diphenylphosphoryl azide (3.12 ml). The solution was heated slowly to reflux and heating continued at reflux overnight. The reaction mixture was then allowed to cool, poured into water (150 ml) and extracted with ethyl acetate (3 x 100 ml). The combined extracts were dried ($MgSO_4$), filtered and evaporated. The crude product was purified by column chromatography, eluting with 5% ethyl acetate in hexane, to give a white solid (1.69 g).

MS (ES) 276 ($M-H$) .

25

¹H NMR (DMSO-D6) 1.44 (s, 9H), 7.03 (s, 1H), 7.51 (s, 1H), 9.65 (s, 1H).

c) 5-Bromo-3-[(*t*-butyloxycarbonyl)amino]thiophene-2-carboxylic acid

2-Bromo-4-(*N*-*t*-butyloxycarbonyl)aminothiophene (1.68 g) was stirred in dry THF (45 ml) under argon and the solution was cooled to - 78 °C. Lithium diisopropylamide (7.55 ml, 2M solution) was added dropwise and stirring continued for 3.5h. Powdered CO₂ (excess)

was added and the mixture stirred for a further 10 minutes before allowing to warm to room temperature. Water (50 ml) was added, the THF was removed *in vacuo* and the aqueous phase was extracted with ethyl acetate (3 x 40 ml). The combined extracts were washed with 1M HCl solution (50 ml), water (50 ml) and brine (50 ml), dried (MgSO_4),
5 filtered and the solvent evaporated. The residue was triturated with dichloromethane and the product collected by filtration as a pale yellow solid (1.57 g).

MS (ES) 320 (M-H)⁺.

¹H NMR (DMSO-D6) 9.38 (s, 1H), 7.79 (s, 1H), 1.42 (s, 9H).

10 d) 5-Bromo-3-(*t*-butyloxycarbonyl)aminothiophene-2-carboxamide

5-Bromo-3-[(*t*-butyloxycarbonyl)amino]thiophene-2-carboxylic acid (0.80 g) was stirred in acetonitrile (80 ml). Hydroxybenztriazole (1.41 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.62 g) were added and stirring continued at room temperature for 10 minutes. Concentrated aqueous ammonia solution (8 ml) was added
15 and the reaction mixture was heated to reflux for 1h. The acetonitrile was removed by evaporation. Water (100 ml) was added and the mixture was sonicated and triturated. The resultant off-white solid was then collected by filtration, washed with water and dried under vacuum (0.763 g).

MS (ES) 319 (M-H)⁺.

20 ¹H NMR (DMSO-D6) 1.45 (s, 9H), 7.63 (brs, 2H), 7.78 (s, 1H), 10.40 (s, 1H).

e) 3-Amino-5-bromothiophene-2-carboxamide

5-Bromo-3-(*t*-butyloxycarbonyl)aminothiophene-2-carboxamide (0.76 g) was stirred in dichloromethane (30 ml). Trifluoroacetic acid (5 ml) was added, the solution was stirred at
25 room temperature for 1 h, poured into saturated aqueous sodium hydrogen carbonate solution (200 ml) and extracted with dichloromethane (3 x 100 ml). The combined extracts were washed with brine (150 ml), dried (magnesium sulphate), filtered and evaporated to give a yellow solid (0.511 g).

MS (ES) 221 (M+H)⁺.

30 ¹H NMR (DMSO-D6) 6.50 (brs, 2H), 6.69 (s, 1H), 6.87 (brs, 2H).

f) 3-[(Aminocarbonyl)amino-5-bromothiophene-2-carboxamide

The title compound was prepared from 3-amino-5-bromothiophene-2-carboxamide in a similar manner to Example 1(b).

5 MS (ES) 264 ($M+H$)⁺.

¹H NMR (DMSO-D6) 6.63 (brs, 2H), 7.41 (brs, 2H), 7.97 (s, 1H), 10.02 (s, 1H).

g) 3-[(Aminocarbonyl)amino-5-(1-benzothien-3-yl)thiophene-2-carboxamide

3-[(Aminocarbonyl)amino-5-bromothiophene-2-carboxamide (0.222 g) and 1-benzothien-

10 3-ylboronic acid (0.449 g) were sonicated in 1,2-dimethoxyethane (15 ml) and saturated aqueous sodium hydrogen carbonate solution (3.5 ml) and purged with argon.

Tetrakis(triphenylphosphine)-palladium (95 mg) was added and the mixture was heated at reflux with stirring for 4.5 h, then allowed to cool and stirred at room temperature overnight. The solution was filtered and washed through with 1,2-dimethoxyethane and water. The filtrate was concentrated in vacuo and taken up in dichloromethane (20 ml) and saturated aqueous sodium hydrogen carbonate solution (20 ml). The solid product was collected by filtration, washed with dichloromethane, water, diethyl ether and dried (226 mg).

MS (ES) 318 ($M+H$)⁺.

20 ¹H NMR (DMSO-D6) 6.60 (brs, 2H), 7.35–7.56 (m, 4H), 8.04 (s, 1H), 8.10 (t, 2H), 8.25 (s, 1H), 10.08 (s, 1H).

Example 122-[(Aminocarbonyl)amino]-5-(2-morpholin-4-ylmethylbenzo[b]thiophen-5-yl)thiophene-3-carboxamide

4-(5-Bromobenzo[b]thiophen-2-ylmethyl)morpholine (Beilstein Reg. No. 1115497)

(230 mg) in dry THF was treated with triisopropyl borate (291 mg) and was cooled under

30 argon to < -70 °C with stirring. After dropwise addition of n-butyl lithium (0.921 ml, 1.6M

in hexanes) the reaction was allowed to warm to room temperature. The solvent was evaporated and replaced with a mixture of dimethoxyethane (20 ml) and saturated aqueous sodium hydrogen carbonate (9 ml). To this mixture was added under argon 2-[(aminocarbonyl)amino]-5-bromothiophen-3-carboxamide (98 mg) and *tetrakis*-triphenyl phosphine palladium (0) (25 mg) and the reaction heated to 90 °C for 1.5 h. The reaction mixture was evaporated to remove the bulk of the organics and the residue distributed between 2M aqueous sodium hydroxide (30 ml) and dichloromethane. After filtering, the organic phase was separated and extracted with a further volume of sodium hydroxide solution (10 ml). The combined aqueous extracts were acidified to pH 8 and filtered. After 10 drying the solid was triturated with diethyl ether and dried to give a powder (27 mg).

LCMS 417 (M+H)⁺.

¹H NMR (DMSO-D6) 2.47 (m, 4H), 3.65 (m, 4H), 3.80 (s, 2H), 6.95 (brs, 2H), 7.3 (brs, 1H), 7.33 (s, 1H), 7.5 (m, 1H), 7.69 (brs, 1H), 7.75 (s, 1H), 7.91 (m, 2H), 11.0 (s, 1H).

15

Example 13

2-[(Aminocarbonyl)amino]-5-[4-(2-morpholin-4-yloxy)-1-benzothien-2-yl]-3-thiophenecarboxamide

20 a) The title compound was prepared from 4-[2-(1-benzothien-4-yloxy)ethyl]morpholine in a similar manner to Example 12, except that the reaction mixture was heated at 90 °C for 4 h. After removing the solvent *in vacuo*, the residue was treated with 3M sodium carbonate/dichloromethane and the solid filtered from the interface. Purification by preparative hplc gave the product.

25 MS (ES) 447 (M+H)⁺.

¹H NMR (DMSO-D6) 2.5 (m, 4H), 2.8 (t, 2H), 3.55 (m, 4H), 4.25 (t, 2H), 7.0 (m, 3H), 7.15 (m, 2H), 7.35 (m, 3H), 7.8 (m, 1H), 11.05 (brs, 1H).

b) 4-[2-[(1-Benzothien-4-yloxy)ethyl]morpholine

4-(2-Chloroethyl)morpholine hydrochloride (0.74 g), 1-benzothiophene-4-ol (0.5 g) and potassium carbonate (1.1 g) in dimethylformamide (15 ml) were heated and stirred at 80 °C for 6 h. After cooling, the mixture was poured into water and extracted twice with ethyl acetate. The combined solvent phase was washed twice with brine, dried (magnesium sulphate) and evaporated to give the product (0.7 g).

5 MS (ES) 264 (M+H)⁺.

¹H NMR (DMSO-D6) 2.5 (m, 4H), 2.8 (t, 2H), 3.55 (m, 4H), 4.25 (t, 2H), 6.9 (d, 1H),
7.25 (t, 1H), 7.4 (d, 1H), 7.55 (d, 1H), 7.6 (d, 1H).

10 c) 1-Benzothiophene-4-ol

The compound was prepared as described in *J.Amer.Chem.Soc.*, 1955, 77, 5939.

Example 14

15 2-[(Aminocarbonyl)amino]-5-{2-[4-methylphenylsulphonyl]-1,2,3,4-tetrahydroisoquinolin-6-yl}thiophene-3-carboxamide

a) The title compound was prepared from 6-bromo-2-[4-methylphenylsulphonyl]-1,2,3,4-tetrahydroisoquinoline in a similar manner to Example 13, except that the reaction mixture was heated at 80 °C for 18 h. After removing the solvent *in vacuo*, the residue was treated with 2M sodium hydroxide and dichloromethane and the separated aqueous phase was adjusted to pH 8 using 36% hydrochloric acid. The crude product was purified by preparative hplc.

20 MS (ES) 471 (M+H)⁺.
¹H NMR (DMSO-D6) 2.4 (s, 3H), 2.8 (m, 2H), 3.2 (m, 2H), 4.1 (s, 2H), 6.9 (br, 2H),
7.15 (m, 1H), 7.3 (m, 1H), 7.4 (m, 2H), 7.5 (m, 1H), 7.7-7.9 (m, 5H), 11.0 (s, 1H).

b) 6-Bromo-2-[4-methylphenylsulphonyl]-1,2,3,4-tetrahydroisoquinoline
2-[3-Bromophenyl]-N-(4-methylphenylsulphonyl)ethylamine (7.44 g) was stirred in
30 chloroform (100 ml) under argon at 5 °C during the sequential addition of 37-40%

formaldehyde (3.5 ml) and phosphorus oxychloride (30 ml). The mixture was then refluxed for 3 h, cooled, poured into dichloromethane (250 ml) / saturated sodium bicarbonate (300 ml) and solid sodium bicarbonate (160 g) cautiously added in portions at 5 °C. The aqueous phase was further extracted with dichloromethane and the combined organic phases washed with saturated sodium bicarbonate and water, dried (MgSO_4) and evaporated to give an oil, which crystallised from isohexane / toluene to give the product (3.48 g).

5 MS (ES) 365 (M^+).

^1H NMR (CDCl_3) 2.43 (s, 3H), 2.89 (t, 2H), 3.34 (t, 2H), 4.18 (s, 2H), 6.89 (d, 1H),
10 7.23 – 7.30 (m, 2H obscured), 7.33 (d, 2H), 7.72 (d, 2H).

c) 2-[3-Bromophenyl]-N-(4-methylphenylsulphonyl)ethylamine

3-Bromophenylethylamine hydrochloride (9.44 g) was added to THF (60 ml) containing triethylamine (12.24 ml) and stirred under argon at 5 °C during the portionwise addition over 15 minutes of 4-methylphenylsulphonyl chloride (11.44 g). The slurry was diluted with THF (50 ml) and stirred for 16 h. The solid was filtered off, washed with THF and the filtrate evaporated. The residue was dissolved in ethyl acetate, washed with 1N hydrochloric acid, water, brine and dried (MgSO_4). Chromatography on flash silica, eluting with 0 to 25% ethyl acetate in isohexane gave the product (9.67 g).

20 MS (ES) 352 ($\text{M}-\text{H}^-$).

^1H NMR (CDCl_3) 2.44 (s, 3H), 2.74 (t, 2H), 3.23 (q, 2H), 4.36 (t, 1H), 7.03 (d, 1H),
7.14 (t, 1H), 7.17 (m, 1H), 7.30 (d, 2H), 7.35 (dd, 1H), 7.69 (dd, 2H).

d) 3-Bromophenylethylamine hydrochloride

25 The free base of the title compound has CAS Registry Number 58971-11-2 and Beilstein Registry Number 2716071.

Example 15

30 3-[(Aminocarbonyl)amino]-5-(1-benzothien-2-yl)thiophene-2-carboxamide

The title compound was prepared from 3-[(aminocarbonyl)amino-5-bromothiophene-2-carboxamide and 1-benzothien-2-ylboronic acid in a similar manner to Example 11 (g).
MS (ES) 318 (M+H)⁺.

5 ¹H NMR (DMSO-D6) 6.64 (brs, 2H), 7.33 – 7.47(m, 2H), 7.49 (brs, 2H), 7.71 (s, 1H),
7.80 – 7.90 (m, 1H), 7.90 – 8.02 (m, 1H), 8.23 (s, 1H), 10.05 (s, 1H).

10

Pharmacological Evaluation of Compounds

IKK2 Filter Kinase Assay

Compounds were tested for inhibition of IKK2 using a filter kinase assay. The test compounds were dissolved to 10 mM in dimethylsulphoxide (DMSO). The compounds 15 were then diluted 1 in 40 in kinase buffer (50 mM Tris, pH 7.4 containing 0.1 mM EGTA, 0.1 mM sodium orthovanadate and 0.1% β-mercaptoethanol). 1 in 3 serial dilutions were made from this solution with 2.5% DMSO in kinase buffer. 20 µl of compound dilution was added to wells of a 96 well plate in duplicate. 20 µl 2.5% DMSO in kinase buffer instead of compound was added to control wells (0% inhibition). 20 µl 0.5 M EDTA was 20 added instead of compound to background wells (100 % inhibition).

10 µl of a mixture of magnesium acetate, unlabelled ATP, and ³³P-labelled ATP was added to each well made such that the final concentration was 10 mM magnesium acetate, 1 µM ATP and 0.1 µCi ³³P ATP. 20 µl of a mixture of IKK2 (0.15 µg/well), 1-53 GST-IκB (0.5 µg /well) and bovine serum albumin (BSA) (8.5 µg/well) was added to each well to start 25 the reaction. The final reaction volume was 50 µl.

The kinase reactions were incubated at 21 °C for 80 minutes and the reaction stopped by precipitating the protein by the addition of an equal volume (50 µl) of 20 % trichloroacetic acid (TCA). The precipitate was allowed to form for 10 minutes and then filtered onto a 30 GF/C unifilter 96 well plate. Each filter was washed twice with approximately 1 ml 2 %

TCA. The filter plate was dried at 30-40 °C for 60 minutes, 20 µl scintillant was added to each well and the plate sealed and radioactivity counted on a Packard Topcount microplate scintillation counter.

5 When tested in the above assay, the compounds of Examples 1 to 15 gave IC₅₀ values of less than 10 µM indicating that they are expected to show useful therapeutic activity.

IKK1 Filter Kinase Assay

10 The selectivity of compounds was assessed by testing them for inhibition of IKK1 using a filter kinase assay. The assay conditions were identical to the IKK2 filter kinase assay except that a mixture of IKK1 (0.25 µg/well) and 1-53 GST IκB (9 µg/well) was added to each well to start the reaction.

15 Inhibition of LPS-induced TNFα production by PBMCs

The effect of test compounds on nuclear factor kappa B (NFκB) activation in cells was assessed by measuring inhibition of tumour necrosis factor alpha (TNFα) production by human peripheral blood mononuclear cells (PBMCs) stimulated by bacterial lipopolysaccharide (LPS).

20 Human blood (250 ml), anticoagulated with heparin, was collected from healthy volunteers. Aliquots of blood (25 ml) were layered on 20 ml Lymphoprep (Nycomed) in 50 ml polypropylene centrifuge tubes. The tubes were centrifuged (Sorval RT600B) at 2,500 rpm for 30 minutes. The cloudy layer containing PBMCs was collected with a fine tipped Pasteur pipette, transferred into 8 clean polypropylene centrifuge tubes (approximately 10 ml per tube) and diluted to 50 ml with phosphate-buffered saline (PBS). These tubes were centrifuged at 2,000 rpm for 8 minutes. PBS (10 ml) was added to each cell pellet and the cells were gently re-suspended. The cells were pooled in 4 centrifuge tubes, PBS was added to each tube to make the volume up to 50 ml and the tubes were 25 centrifuged at 1,400 rpm for 8 minutes. The cell pellets were again re-suspended in 10 ml PBS, pooled in 2 centrifuge tubes, the volume made up to 50 ml with PBS and the tubes 30 centrifuged at 900 rpm for 10 minutes.

The final cell pellets were gently re-suspended in 10 ml tissue culture medium (RPMI containing 1% heat-inactivated human serum, L-glutamine and penicillin and streptomycin), combined into 1 tube and the volume made up to 30 ml with RPMI medium. The cells were counted and the cell suspension was diluted to 2.6×10^6 cells/ml.

Test compounds were dissolved in DMSO to 10 mM and diluted 1 in 250 (40 μ M) with RPMI medium. The compounds were then serially diluted 1 in 3 with 0.4% DMSO in RPMI medium. Aliquots of test compound dilutions (50 μ l) were transferred to the wells of a 96-well plate. Control wells contained 0.4% DMSO in RPMI instead of compound.

Aliquots of the cell suspension (100 μ l) were added to each well and the plates incubated at 37°C for 30 minutes. 50 μ l of 40 μ g/ml LPS (Sigma, L-4130) was added to wells to stimulate TNF α production by the cells and the plates were incubated overnight at 37°C. RPMI medium (50 μ l) was added to negative control wells instead of LPS. The final incubation volume was 200 μ l.

Plates were centrifuged for 4 minutes at 1,200 rpm and supernatants were removed for measurement of TNF α concentration. Viability of the remaining cell pellet was measured using WST-1 reagent (Boehringer Mannheim, 1044807). 100 μ l RPMI medium containing 10 μ l WST-1 reagent was added to each well and the plates were incubated for 0.5 to 3 h. The absorbance at 450 nm was then measured using a 96-well plate spectrophotometer.

TNF α in the supernatants (freshly harvested or stored frozen at -20°C) were measured using an enzyme-linked immunosorbent assay (ELISA). The ELISA plate was prepared by coating the wells of a 96 well plate with a sheep anti-human TNF α monoclonal antibody (100 μ l of 1 μ g/ml antibody diluted in coating buffer; 0.5 M carbonate/bicarbonate buffer, pH 9.6 containing 0.2 g/l sodium azide) and incubating overnight at 4°C. Blank wells were not coated. The wells were washed once with 0.1% BSA in PBS containing 0.05% Tween (PBS/Tween) then incubated for 1 h at room temperature with 1% BSA in coating buffer (200 μ l). The wells were then washed 3 times with 0.1% BSA in PBS/Tween.

The samples of supernatant from the PBMC incubation were diluted 1 in 3 with 1% BSA in PBS/Tween. 100 μ l aliquots of these dilutions were added to the ELISA plate. Other wells contained 100 μ l TNF α standard (10, 3.3, 1.1, 0.37, 0.12, 0.04, 0.014 and 0 ng/ml).


5 The ELISA plate was incubated at room temperature for 2 h before the wells were washed 3 times with 0.1% BSA in PBS/Tween. A rabbit anti-human TNF α antibody (100 μ l of a 2.5 μ g/ml solution) was added to each well and the plate incubated at room temperature for 1.5 h. The wells were then washed 3 times with 0.1% BSA in PBS/Tween. Goat anti-rabbit IgG-horse radish peroxidase conjugate (ICN, 674371; 100 μ l of a 1 in 10,000 dilution)

10 was added to each well and the plate incubated at room temperature for 1.5 h. The wells were washed 3 times with 0.1% BSA in PBS/Tween.

Peroxidase substrate was prepared by dissolving a 1 mg TMB tablet (Sigma, T-5525) in 100 μ l DMSO (100 μ l) and adding this and 36 μ l UHPO (BDH, 30559; 1 g tablet dissolved in 25 ml distilled water) to 10 ml 0.1M citrate/acetate buffer, pH6. 100 μ l substrate was added to each well and the plate incubated in the dark at room temperature for approximately 30 minutes. The reaction was stopped by adding 25 μ l 2 M sulphuric acid to each well. The absorbance at 450 nm was measured in a 96 well plate spectrophotometer.

CLAIMS

1. A compound of formula (I)



in which:

R^1 represents NH_2 or R^1 represents a methyl group optionally substituted by one or more

10 groups selected independently from C_1-C_4 alkyl, C_3-C_6 cycloalkyl, halogen, hydroxyl, C_1-C_4 alkoxy, $S(O)_vCH_3$ and NR^4R^5 ;

X represents O or S;

15 R^2 represents hydrogen, halogen, cyano, nitro, $-NR^6R^7$, $-CONR^6R^7$, $-COOR^6$, $-NR^6COR^7$, $-S(O)_mR^6$, $-SO_2NR^6R^7$, $-NR^6SO_2R^7$, C_1-C_2 alkyl, trifluoromethyl, C_2-C_3 alkenyl, C_2-C_3 alkynyl, trifluoromethoxy, C_1-C_2 alkoxy or C_1-C_2 alkanoyl;

20 A represents a fused bicyclic ring system wherein one ring is a phenyl ring or a 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S; and the other ring is either a fused phenyl ring or a fused 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently

from O, N and S; or a fused 5- to 7-membered saturated ring optionally incorporating one to three heteroatoms selected independently from oxygen, nitrogen and sulphur; said fused bicyclic ring system being optionally substituted by one or more substituents selected independently from halogen, cyano, nitro, -NR⁸COR⁹, -S(O)_nR⁸, -SO₂NR⁸R⁹,

5 -NR⁸SO₂R⁹ and C₁-C₆ alkyl;

n represents an integer 0, 1 or 2; and when n represents 2, each R³ group may be selected independently;

10 R³ represents a group -W-Y-Z wherein:

W represents O, S(O)_r, NR¹³, CH₂, -CH₂-O- or a bond;

15 Y represents a bond or Y represents a group -(CH₂)_p-X-(CH₂)_q- wherein p and q independently represent an integer 0, 1 or 2; and X represents O, -CO- or CR¹⁴R¹⁵;

R¹⁴ and R¹⁵ independently represent H, CH₃ or F;

or R¹⁴ represents H or CH₃ and R¹⁵ represents hydroxyl or OCH₃;

20

or the group CR¹⁴R¹⁵ together represents a C₃-C₆ cycloalkyl ring;

Z represents:

25 (a) a phenyl ring or a 5- or 6-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S; said phenyl or heteroaromatic ring being optionally substituted by one or more substituents selected independently from halogen, cyano, -NR¹⁶R¹⁷, -CONR¹⁶R¹⁷, -COOR¹⁶, -COR¹⁶, -NR¹⁶COR¹⁷, -S(O)_uR¹⁶,

-SO₂NR¹⁶R¹⁷, -NR¹⁶SO₂R¹⁷, hydroxyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkyl and C₁-C₆ alkoxy; said alkyl or alkoxy group being optionally further substituted by one or more groups selected from halogen, cyano, hydroxyl, C₁-C₄ alkoxy and NR¹⁸R¹⁹; or

5 (b) a saturated 3- to 7-membered ring optionally incorporating one or two heteroatoms selected independently from O, N and S, and optionally incorporating a carbonyl group; said saturated ring being optionally substituted by one or more substituents selected independently from halogen, cyano, -NR¹⁶R¹⁷, -CONR¹⁶R¹⁷, -COOR¹⁶, -COR¹⁶, -NR¹⁶COR¹⁷, -S(O)_uR¹⁶, -SO₂NR¹⁶R¹⁷, -NR¹⁶SO₂R¹⁷, hydroxyl, C₂-C₆ alkenyl, 10 C₂-C₆ alkynyl, C₁-C₆ alkyl and C₁-C₆ alkoxy; said alkyl or alkoxy group being optionally further substituted by one or more groups selected from halogen, cyano, hydroxyl, C₁-C₄ alkoxy and NR¹⁸R¹⁹; or

15 (c) Z represents hydroxyl, C₁-C₆ alkoxy, CF₃, CHF₂, CH₂F or NR²⁰R²¹ where R²⁰ and R²¹ are independently hydrogen or C₁-C₆ alkyl optionally substituted by C₁-C₄ alkoxy;

20 R⁴ and R⁵ independently represent H or C₁-C₄ alkyl; or the group NR⁴R⁵ represents a 5- or 6-membered saturated azacyclic ring optionally containing a further O, S or NR²³ group; where R²³ is hydrogen or C₁-C₄ alkyl;

25 R⁶ and R⁷ independently represent H or C₁-C₂ alkyl;

R⁸ and R⁹ independently represent H or C₁-C₆ alkyl;

25 R¹³ represents H or C₁-C₄ alkyl;

R¹⁶ and R¹⁷ independently represent H or C₁-C₆ alkyl; or the group NR¹⁶R¹⁷ represents a 5- or 6-membered saturated azacyclic ring optionally containing a further O, S or NR²⁴ group; where R²⁴ is hydrogen or C₁-C₆ alkyl;

5 R¹⁸ and R¹⁹ independently represent H or C₁-C₄ alkyl; or the group NR¹⁸R¹⁹ represents a 5- or 6-membered saturated azacyclic ring optionally containing a further O, S or NR²⁵ group; where R²⁵ is hydrogen or C₁-C₄ alkyl;

m, r, s, u and v independently represent an integer 0, 1 or 2;

10

and pharmaceutically acceptable salts thereof.

2. A compound of formula (I), according to Claim 1, wherein X represents oxygen.

15

3. A compound of formula (I), according to Claim 1 or Claim 2, wherein R¹ represents NH₂.

20 4. A compound of formula (I), according to any one of Claims 1 to 3, in which R² represents H or methyl.

25 5. A compound of formula (I), according to claim 1, selected from:

2-[(aminocarbonyl)amino]-5-(2-benzofuranyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(3-quinolinyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(8-quinolinyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(2-benzothiophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(3-benzothiophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(5-indolyl)-3-thiophenecarboxamide;


2-[(aminocarbonyl)amino]-4-methyl-5-(1,4-benzodioxan-6-yl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-indolyl)-3-thiophenecarboxamide;
 2-[(aminocarbonyl)amino]-4-methyl-5-(1,3-benzodioxo-5-yl)-3-thiophenecarboxamide;
 2-[(aminocarbonyl)amino]-5-(1*H*-indol-2-yl)thiophene-3-carboxamide;
 3-[(aminocarbonyl)amino]-5-(1-benzothien-3-yl)thiophene-2-carboxamide;
 5 2-[(aminocarbonyl)amino]-5-(2-morpholin-4-ylmethylbenzo[b]thiophen-5-yl)thiophene-3-carboxamide;
 2-[(aminocarbonyl)amino]-5-[4-(2-morpholin-4-yloxy)-1-benzothien-2-yl]-3-thiophenecarboxamide;
 10 2-[(aminocarbonyl)amino]-5-{2-[4-methylphenylsulphonyl]-1,2,3,4-tetrahydroisoquinolin-6-yl}thiophene-3-carboxamide;
 3-[(aminocarbonyl)amino]-5-(1-benzothien-2-yl)thiophene-2-carboxamide;
 and pharmaceutically acceptable salts thereof.

6. A process for the preparation of a compound of formula (I), according to any one of

15 Claims 1 to 5, which comprises:


(a) reaction of a compound of formula (II):



wherein A, R², R³ and n are as defined in Claim 1 with an isocyanate or an isothiocyanate


20 or an acyl derivative, R¹-CO-L, where L is a leaving group; or

(b) reaction of compound of formula (III)



wherein R^3 , n and A are as defined in Claim 1

with a compound of formula (IV)




5

wherein X, R^1 and R^2 are as defined in Claim 1 and LG represents a leaving group; or


(c) reaction of compound of formula (V)

10



wherein R^3 , n and A are as defined in Claim 1 and LG represents a leaving group,
with a compound of formula (VI)

15



wherein X, R¹ and R² are as defined in Claim 1;

- 5 and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.
- 10 7. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 15 8. A process for the preparation of a pharmaceutical composition as claimed in Claim 7 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5 with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 20 9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5 for use as a medicament.
- 25 10. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5, in the manufacture of a medicament for use in the treatment or prophylaxis of diseases or conditions in which inhibition of IKK2 activity is beneficial.

11. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5 in the manufacture of a medicament for use in the treatment or prophylaxis of inflammatory disease.
- 5 12. The use as claimed in Claim 11 wherein the disease is asthma.
13. The use as claimed in Claim 11 wherein the disease is rheumatoid arthritis.
14. The use as claimed in Claim 11 wherein the disease is multiple sclerosis.
- 10 15. The use as claimed in Claim 11 wherein the disease is chronic obstructive pulmonary disease.
16. The use as claimed in Claim 11 wherein the disease is cancer.
- 15 17. A method of treating, or reducing the risk of, diseases or conditions in which inhibition of IKK2 activity is beneficial which comprises administering to a person suffering from or at risk of said disease or condition a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 5.
- 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01402

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 407/04, C07D 409/04, A61K 31/381, A61K 31/47, A61K 31/404
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 1468012 A (BEECHAM GROUP LIMITED), 23 March 1977 (23.03.77) --	1-16
A	EP 0853083 A1 (PFIZER INC.), 15 July 1998 (15.07.98) --	1-16
A	WO 0071532 A1 (PFIZER PRODUCTS INC.), 30 November 2000 (30.11.00) -- -----	1-16

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier application or patent but published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 October 2002	05-11-2002
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86	Authorized officer Göran Karlsson/EÖ Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE02/01402**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **17**
because they relate to subject matter not required to be searched by this Authority, namely:
**A method for treatment of the human or animal body by therapy,
see rule 39.1**
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

30/09/02

PCT/SE 02/01402

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
GB	1468012	A	23/03/77	US 3963750 A	15/06/76
EP	0853083	A1	15/07/98	SE 0853083 T3 AT 205494 T BR 9800228 A CA 2226039 A DE 69706642 D, T DK 853083 T ES 2161418 T JP 10195070 A PT 853083 T US 6048880 A US 2002022729 A	15/09/01 08/09/99 06/07/98 07/02/02 19/11/01 01/12/01 28/07/98 28/12/01 11/04/00 21/02/02
WO	0071532	A1	30/11/00	AU 4137400 A BR 0010746 A EP 1187826 A US 6380214 B	12/12/00 13/02/02 20/03/02 30/04/02

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)